An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2002-.
Top results in this bookTable of Contents
Addendum to Haematological Cancers: improving outcomes (update).
National Collaborating Centre for Cancer (UK).
London: National Institute for Health and Care Excellence (NICE); 2016 May.
Neutropenic Sepsis: Prevention and Management of Neutropenic Sepsis in Cancer Patients.
London: National Institute for Health and Clinical Excellence (NICE); 2012 Sep. (NICE Clinical Guidelines, No. 151.)
WHO Guidelines for Indoor Air Quality: Selected Pollutants.
Geneva: World Health Organization; 2010.
Non-Hodgkin's Lymphoma: Diagnosis and Management.
National Guideline Alliance (UK).
London: National Institute for Health and Care Excellence (NICE); 2016 Jul. (NICE Guideline, No. 52.)
Suspected cancer: recognition and referral.
London: National Institute for Health and Care Excellence (NICE); 2023 Oct 24. (NICE Guideline, No. 12.)
Spinal Injury: Assessment and Initial Management.
National Clinical Guideline Centre (UK).
London: National Institute for Health and Care Excellence (NICE); 2016 Feb. (NICE Guideline, No. 41.)
Blood Transfusion.
London: National Institute for Health and Care Excellence (NICE); 2015 Nov. (NICE Guideline, No. 24.)
Nelarabine (Atriance): CADTH Reimbursement Recommendation: Indication: Nelarabine (Atriance) for addition to front-line multiagent therapy of pediatric, adolescent, and young adult patients (aged 1 year to 30 years at diagnosis) with intermediate- or high-risk T-cell acute lymphoblastic leukemia [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Oct.
Calaspargase Pegol (Asparlas): CADTH Reimbursement Recommendation: Indication: As a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 to 21 years [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Jan.
Ivosidenib (Tibsovo): Indication: Ivosidenib in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy: Reimbursement Recommendation [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Oct.
Cancer Control: Knowledge Into Action: WHO Guide for Effective Programmes: Module 4: Diagnosis and Treatment.
Geneva: World Health Organization; 2008.
Zanubrutinib (Brukinsa): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with chronic lymphocytic leukemia [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Sep.
Brexucabtagene Autoleucel (Tecartus): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Apr.
Treosulfan (Trecondyv): CADTH Reimbursement Recommendation: Indication: Treosulfan in combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia or myelodysplastic syndromes at increased risk for standard conditioning therapies [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Mar.
Ibrutinib (Imbruvica): CADTH Reimbursement Recommendation: Indication: Ibrutinib in combination with venetoclax for the treatment of adult patients with previously untreated chronic lymphocytic leukemia, including those with 17p deletion [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Nov.
Asciminib (Scemblix): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) previously treated with 2 or more tyrosine kinase inhibitors [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Aug.
The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research.
National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda.
Washington (DC): National Academies Press (US); 2017 Jan 12.
Avapritinib (Ayvakyt): Indication: For the treatment of adult patients with advanced systemic mastocytosis (AdvSM). AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL): Reimbursement Recommendation [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Nov.
Selinexor (Xpovio): CADTH Reimbursement Recommendation: Indication: Multiple myeloma [Internet].
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on